



Resonance Health Ltd
ASX / Media Release

18 March 2013

New Drug Trial Using FerriScan[®]

Resonance Health has signed a significant multi-year contract with a major European pharmaceutical company for the provision of FerriScan[®] services in their clinical trial of a new drug, for an undisclosed sum.

Patients participating in the clinical trial are being treated for iron overload with a new therapy to chelate (remove) iron from their organs.

The contract involves the provision of Resonance Health's FerriScan services to a large number of MRI facilities across several countries. Resonance Health will be providing FerriScan liver iron concentration measurements for patients enrolled in the study together with a range of project management services.

FerriScan[®] is considered the international gold standard for the non-invasive measurement of liver iron, replacing the need for patients to have a liver biopsy. This enables patients to safely have repeat measurements over the course of their treatment providing a significant benefit to clinical trials where repeat measurements are required.

By Order of the Board
Resonance Health Limited

For further information please
contact:

Resonance Health

Liza Dunne

Managing Director

T: +61 8 9286 5300

E: lizad@resonancehealth.com

Naomi Haydari

Company Secretary

T: +61 8 9286 5300

E: naomih@resonancehealth.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing imaging core laboratory services for the quantitative analysis of medical images, with a subspecialty in the liver. Resonance Health's patented FerriScan technology provides a safe and accurate alternative for measuring liver iron concentration, and research continues into the development of new technology for the accurate assessment of liver fat and liver fibrosis.